NCT07412236尚未招募3 期
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIIc Clinical Study Evaluating the Long-term Treatment of Hepatic Fibrosis in Chronic Hepatitis B With Hydronidone Capsules.
Beijing Continent Pharmaceutical Co, Ltd.1 个研究点 分布在 1 个国家目标入组 1,208 人开始时间: 2026年1月30日最近更新:
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 1,208
- 试验地点
- 1
- 主要终点
- Incidence of Clinical Endpoint Events
研究概览
简要总结
This study is conducted as a randomized, double-blind, placebo-controlled, multicenter clinical trial on a background of entecavir therapy. It aims to evaluate the clinical benefits of Hydronidone Capsules in patients with liver fibrosis due to chronic hepatitis B. The study consists of a Screening/Baseline Period (4 weeks) and a Dosing/Observation Period (planned duration of 5 years, including a 52-week primary treatment phase and a 208-week long-term treatment phase).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18 to 65 years (inclusive of 18 and 65 years old at the time of signing the informed consent form), male or female;
- •Documented history of chronic hepatitis B and/or positive for hepatitis B surface antigen (HBsAg) for ≥6 months;
- •Treatment-naïve or treatment-experienced patients with chronic hepatitis B, defined as follows:
- •Treatment-naïve patients must meet all of the following criteria:
- •No prior systemic antiviral therapy (e.g., interferon and/or nucleos(t)ide analogues) before randomization;
- •Positive for HBV DNA;
- •Liver stiffness measurement (LSM) by transient elastography ≥12.4 kPa for treatment-naïve patients with ALT >2 × ULN; or LSM ≥10.6 kPa for treatment-naïve patients with ALT ≤2 × ULN. Subjects whose LSM does not meet the above criteria may still be enrolled if they have liver biopsy evidence (within the past 6 months) confirming liver fibrosis of Ishak score ≥
- •Treatment-experienced patients must meet all of the following criteria:
- •A history of ≥6 months of continuous nucleos(t)ide analogue therapy for hepatitis B up to randomization, currently receiving monotherapy with a nucleos(t)ide analogue [e.g., Tenofovir Alafenamide Fumarate (TAF), Tenofovir Disoproxil Fumarate (TDF), or Entecavir (ETV)];
- •HBV DNA positive or negative is acceptable;
- •Liver stiffness measurement (LSM) by transient elastography >9.0 kPa. Subjects whose LSM does not meet the above criteria may still be enrolled if they have liver biopsy evidence (within the past 6 months) confirming liver fibrosis of Ishak score ≥
- •ALT <8 × ULN;
- •No use within 3 months prior to randomization of the following Chinese patent medicines that may have antifibrotic effects: Fuzhenghuayu Capsule (Tablet), Anluohuaxian Pill, Compound Biejia Ruangan Tablet, etc.;
- •Subjects (or their sexual partners) have no pregnancy plan during the trial and for 6 months after trial completion, voluntarily agree to use effective physical contraceptive methods, and have no plan to donate sperm or eggs;
- •Subjects have fully understood the nature, significance, potential benefits, possible inconveniences, and potential risks of the trial prior to participation, voluntarily agree to take part in this clinical trial, are able to communicate well with the investigators, agree to comply with all study requirements, and have provided written informed consent.
排除标准
- •Total bilirubin (TBil) >3 × ULN, or 3 × ULN < ALT <8 × ULN with TBil >2 × ULN;
- •Platelet count (PLT) ≤50 × 10⁹/L;
- •Prothrombin activity (PTA) <50% or International Normalized Ratio (INR) >1.5;
- •Imaging findings suggestive of a space-occupying lesion in the liver indicative of tumor, or alpha-fetoprotein (AFP) >100 μg/L even in the absence of specific signs of hepatocellular carcinoma;
- •Patients with decompensated liver cirrhosis (complications including ascites, esophageal and/or gastric variceal bleeding, spontaneous bacterial peritonitis, hepatorenal syndrome, hepatopulmonary syndrome, hepatic encephalopathy, portal vein thrombosis, and cirrhotic cardiomyopathy) or with hepatic malignancy;
- •Patients with chronic hepatitis C or non-viral chronic hepatitis (alcoholic, drug-induced, etc., excluding metabolic dysfunction-associated steatotic liver disease (MASLD));
- •History of alcohol abuse or inability to abstain from alcohol recently [Note: Alcohol abuse is defined as: ① daily ethanol consumption ≥40 g for males or ≥20 g for females for 5 consecutive years; OR ② history of heavy alcohol consumption (>80 g of ethanol per day) within the past 2 weeks. Ethanol (g) = volume of alcoholic beverage consumed (mL) × alcohol by volume (%) × 0.8];
- •Patients with severe concurrent cardiovascular, pulmonary, renal, endocrine, neurological, or hematological diseases, or psychiatric disorders;
- •Pregnant and/or lactating women;
- •Participation in any other drug clinical trial within the past 3 months;
- •Any condition that, in the investigator's judgment, may affect the subject's ability to provide informed consent or comply with the trial protocol, or participation that may affect the trial results or the subject's own safety.
研究组 & 干预措施
Hydronidone Capsule Group (270 mg)
Experimental
Treatment Group
干预措施: Hydronidone (270mg) (Drug)
Hydronidone Capsule Group (Placebo Group)
Placebo Comparator
Placebo Group
干预措施: Hydronidone (Placebo Group) (Drug)
结局指标
主要结局
Incidence of Clinical Endpoint Events
时间窗: From the first dose administration to the end of the treatment period (Week 261).
The clinical endpoint event is a composite event, which includes progression to complications of decompensated cirrhosis (such as ascites, esophageal and gastric variceal bleeding, spontaneous bacterial peritonitis, hepatorenal syndrome, hepatopulmonary syndrome, hepatic encephalopathy, portal vein thrombosis, and cirrhotic cardiomyopathy, etc.), hepatocellular carcinoma, liver transplantation, and liver disease-related death/all-cause death. The time of event occurrence is determined by whichever occurs first, and the occurrence of any of these events constitutes a clinical endpoint event.
次要结局
- Change from baseline in liver stiffness measurement (LSM) by transient elastography (kPa) after treatment.(From the first dose administration to the end of the treatment period (Week 261).)
- Undetectable rate of Hepatitis B virus deoxyribonucleic acid (HBV DNA) after treatment (below the lower limit of detection).(From the first dose administration to the end of the treatment period (Week 261).)
- Magnitude of reduction in Hepatitis B virus deoxyribonucleic acid (HBV DNA) after treatment.(From the first dose administration to the end of the treatment period (Week 261).)
- Normalization rate of improvement in alanine aminotransferase (ALT) levels after treatment.(From the first dose administration to the end of the treatment period (Week 261).)
- Magnitude of improvement in alanine aminotransferase (ALT) levels after treatment.(From the first dose administration to the end of the treatment period (Week 261).)
- Normalization rate of improvement in aspartate aminotransferase (AST) levels after treatment.(From the first dose administration to the end of the treatment period (Week 261).)
- Magnitude of improvement in aspartate aminotransferase (AST) levels after treatment.(From the first dose administration to the end of the treatment period (Week 261).)
- The annualized incidence rates of individual components of the clinical endpoint events(From the first dose administration to the end of the treatment period (Week 261).)
- Annualized Incidence Rate of Clinical Endpoint Events(From the first dose administration to the end of the treatment period (Week 261).)
- The incidence rates of individual components of the clinical endpoint events(From the first dose administration to the end of the treatment period (Week 261).)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
A Clinical Study Evaluating the Efficacy and Safety of CMS-D001 Tablets in the Treatment of Adult Patients With Moderate to Severe Plaque-type PsoriasisNCT07432854Dermavon Holdings Limited540
尚未招募
3 期
A Phase III Study to Evaluate the Efficacy and Safety of MDR-001 in Adult Participants With Overweight or Obesity (MOBILE）NCT07274137MindRank AI Ltd738
招募中
2 期
Phase II Study of RC1416 Injection in COPDNCT07402551Nanjing RegeneCore Biotech Co., Ltd.180
尚未招募
3 期
Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline for Vaping Cessation in Adults Using Nicotine-Containing E CigarettesNCT07392125Achieve Life Sciences800
已完成
2 期
Live Double Combined Lactobacillus Capsule for Vaginal Use(IIb)Bacterial VaginosisNCT07418918Guangdong Longchuangji Pharmaceutical Co., Ltd.66